BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...

Noblegen adds Craig Cogut and Dr. Rajiv Shah to its Board of Directors and opens its Series C capital raise with a $500M target PETERBOROUGH, Ontario, July 06, 2021 (GLOBE NEWSWIRE) -- Noblegen Inc. (“Noblegen"), an advanced digital biology company, is excited to announce that Craig Cogut, the Founder, Chairman, and CEO of...

Ault Life Sciences Launches $100 Million 506(c) and Regulation S Offering NEWPORT BEACH, Calif., May 07, 2020 (GLOBE NEWSWIRE) --  Ault Life Sciences, Inc. (“ALSI” or the “Company”), a Delaware corporation, announced that it is seeking to raise up to $100 million through...

Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”)...